CorMedix’s CRMD lead product, DefenCath (taurolidine plus heparin), is the company’s primary source of revenues. DefenCath ...

The Pitt season premiere, "7:00 a.m.," ignores clichés in favor of a gritty, realistic, and uncompromising take on the ...

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

Under the leadership of Mr. Todisco, CorMedix has evolved from a single product, development stage company into a multi-product, diversified commercial operation with positive cashflow and a strong ...

A new Indian study warns that the drug-resistant fungus Candida auris is spreading worldwide and becoming deadlier. Led by researchers from Vallabhbhai Patel Chest Institute with support from the ...

Up to 189 health conditions could potentially affect your ability to drive, with seven specific conditions that must be ...

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

The article " Why CorMedix Could be the Biopharma Name to Watch Early in 2026 " first appeared on MarketBeat.

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.

The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.

As many as 189 health conditions could potentially affect your legal ability to drive. Both physical and mental health ...

Drivers could face up to £1,000 fines and potential prosecution if they fail to report notifiable medical conditions or ...